[The effect of selected anticoagulants on the clonogenicity of human hematopoietic progenitors. Transplantation implications].
The aim of the study was to evaluate the toxicity of the various anticoagulants against human clonogenic CD34+ cells. We have been evaluating the toxicity of: heparin (Gibco, USA), heparin (Polfa, Poland) ACD (acid citrate dextrose) solution and CPDA-1 (citrate phosphate dextrose adenine) solution. Using standard concentrations of these anticoagulants, we found that heparin (Gibco, USA) is not toxic to the human early haematopoietic cells. In comparison, the heparin from Polfa, which was found to be not toxic at standard concentrations (20 U/ml), inhibited almost completely the growth of CD34+ cells if used at higher concentrations (2000 U/ml). Interestingly, both ACD and CPDA-1 solutions were also found to possess moderate toxicity, which tends to increase with the prolongation of the exposure time. Therefore, the heparin from Gibco, being well tolerated by clonogenic CD34+ cells, should be recommended as an anticoagulant for harvesting viable haematopoietic cells for transplantation purposes, or for in vitro diagnostic tests.